Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kathryn Kirk

Gastroenterology Chevy Chase, MD Medical Doctor

NPI 1477655371 CMS profile 157181

5550 Friendship Blvd, Suite T-90, Chevy Chase, MD 20815

Open in the dashboard

General payments

$5,154

277 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kathryn Kirk of Chevy Chase, MD is reported in the CMS Open Payments database as having received $5,154 across 277 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,254 63
2024 General $1,074 52
2023 General $1,450 82
2022 General $507 29
2021 General $194 10
2020 General $128 8
2019 General $548 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kathryn Kirk
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Kathryn Kirk were reported at $1,254. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Kathryn Kirk Gastroenterology median Middle half National median
2019 $548 $417 $126–$1,100 $163
2020 $128 $224 $74–$624 $114
2021 $194 $352 $106–$1,054 $132
2022 $507 $448 $129–$1,270 $149
2023 $1,450 $533 $150–$1,390 $160
2024 $1,074 $605 $160–$1,606 $164
2025 $1,254 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,131 57 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $542 28 payments
  3. Celgene Corporation $413 32 payments
  4. Pfizer Inc. $411 22 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $388 28 payments
  6. Janssen Biotech, Inc. $383 21 payments
  7. Lilly USA, LLC $225 11 payments
  8. QOL Medical, LLC $204 7 payments
  9. Genzyme Corporation $191 9 payments
  10. Daiichi Sankyo Inc. $160 8 payments
  11. Other $1,106 54 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,108 274 payments
  2. Education $45 3 payments
Products named General payments · program years 2019–2025
  1. ZEPOSIA $512 33 payments
  2. ENTYVIO $508 26 payments
  3. RINVOQ $486 24 payments
  4. LINZESS $446 24 payments
  5. XIFAXAN $372 24 payments
  6. XELJANZ $326 17 payments
  7. SKYRIZI $258 12 payments
  8. CREON $222 11 payments
  9. STELARA $210 13 payments
  10. DUPIXENT $191 9 payments
  11. Other $2,620 138 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

715

Median for Gastroenterology: 569

Drug cost

$113,771

Median for Gastroenterology: $104,976

Branded share of claims

44.1%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mesalamine Generic 19 $50,121
Linzess Linaclotide Brand 36 $25,185
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 171 $10,614
Dexilant Dexlansoprazole Brand 12 $8,040
Dexlansoprazole Dr Dexlansoprazole Brand 15 $3,981
Omeprazole Generic 155 $3,407
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 16 $2,536
Cholestyramine Cholestyramine (With Sugar) Brand 18 $2,338
Mesalamine Er Mesalamine Brand 15 $2,104
Esomeprazole Magnesium Generic 35 $1,614

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$429,483

Of which drugs: $297,872

Medicare patients

722

Average age 75

Services billed

19,345

561 women, 161 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 58%
Arthritis 45%
Osteoporosis 28%
Ischemic heart disease 20%
Cancer 17%
Diabetes 15%
Depression 15%
Atrial fibrillation 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vedolizumab, 1 mg J3380 Office 27 14,100 $245,247

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $157
$157 — 14,100
SKYRIZI
  • AbbVie, Inc. $109
$109 — —
LINZESS
  • AbbVie, Inc. $85
  • Ironwood Pharmaceuticals, Inc $17
$103 36 —
RINVOQ
  • AbbVie, Inc. $98
$98 — —
ZEPOSIA
  • Celgene Corporation $79
$79 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

277 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record